Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Do Not Edit

2 clinical trials in Do Not Edit, The Netherlands. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Do Not Edit at a glance
2
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Do Not Edit

Open in trial search

Chronic lymphocytic leukaemia

Recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:University Of Cologne

Glomerulonephritis chronic

Recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Region Oestergoetland

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Do Not Edit

What the registry says about research in the country

01 Do Not Edit
Immune System Diseases
Researchers in Do Not Edit are evaluating long‑term outcomes for patients with ANCA-associated vasculitis by comparing relapse rates after stopping versus maintaining rituximab therapy. ANCA-associated vasculitis Rituximab maintenance vs discontinuation Relapse rate as primary endpoint Stable remission cohort The trial aims to inform optimal treatment duration and improve quality of life for individuals living with this autoimmune condition.
Musculoskeletal Diseases
Although current recruiting studies focus on immune and oncologic conditions, the local research community is preparing protocols to address musculoskeletal disorders such as inflammatory arthritis and osteoporosis. Potential focus on rheumatoid arthritis Exploration of biologic therapies Patient‑reported outcome measures Collaboration with orthopedic centers Future investigations are expected to expand the therapeutic portfolio and offer new options for bone and joint health in the region.
Neoplasms
An ambitious trial in Do Not Edit compares a novel combination of pirtobrutinib and epcoritamab against standard R-(mini)-CHOP for individuals with Richter transformation arising from CLL or DLBCL. Richter transformation in untreated patients Targeted BTK inhibition with pirtobrutinib Bispecific antibody epcoritamab Standard chemo‑immunotherapy comparator The study seeks to improve response rates and durability of remission for this aggressive lymphoma subtype.
Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.